NLS Pharmaceutics Ltd.宣布,公司已同意将与Kadimastem的合并协议终止日期从8月31日延长至10月31日。这一决定已通过SEC文件披露。
根据提交的监管文件显示,双方就延长合并协议有效期达成一致,为完成相关交易程序争取更多时间。此次延期将使两家公司有额外两个月的时间来推进合并事宜。
NLS Pharmaceutics Ltd.宣布,公司已同意将与Kadimastem的合并协议终止日期从8月31日延长至10月31日。这一决定已通过SEC文件披露。
根据提交的监管文件显示,双方就延长合并协议有效期达成一致,为完成相关交易程序争取更多时间。此次延期将使两家公司有额外两个月的时间来推进合并事宜。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.